These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31059726)

  • 1. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report.
    Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S
    Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726
    [No Abstract]   [Full Text] [Related]  

  • 2. Three more immune checkpoint inhibitors for advanced bladder cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors Effective in Urothelial Cancer.
    Brower V
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 30053144
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
    Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J
    Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711
    [No Abstract]   [Full Text] [Related]  

  • 5. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
    Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
    Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
    [No Abstract]   [Full Text] [Related]  

  • 6. Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma.
    Wills S; Hochmuth LK; Bauer KS; Deshmukh R
    Curr Probl Cancer; 2019 Jun; 43(3):181-194. PubMed ID: 30270097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
    Le Brun IC; Benderra MA
    Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742
    [No Abstract]   [Full Text] [Related]  

  • 9. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Li R; Spiess PE; Gilbert SM; Necchi A
    Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant pembrolizumab in bladder cancer.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e669. PubMed ID: 30509883
    [No Abstract]   [Full Text] [Related]  

  • 12. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
    Gupta S; Kamat AM
    Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Front-line Metastatic Bladder Cancer is Platinum-free.
    Young M
    Eur Urol Focus; 2024 Mar; 10(2):215-216. PubMed ID: 38658299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
    Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J
    Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab use in bladder cancer: a tale of two trials.
    Aragon-Ching JB
    Nat Rev Urol; 2021 Oct; 18(10):577-578. PubMed ID: 34230659
    [No Abstract]   [Full Text] [Related]  

  • 20. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.